Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03161431
Title SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Syntrix Biosystems, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.